Metformin use and risk of prostate cancer: Results from the REDUCE study

Tom Feng, Xizi Sun, Lauren E. Howard, Adriana C. Vidal, Alexis R. Gaines, Daniel M. Moreira, Ramiro Castro-Santamaria, Gerald L. Andriole, Stephen J. Freedland

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


The role of metformin in prostate cancer chemoprevention remains unclear. REDUCE, which followed biopsy-negative men with protocol-dictated PSA-independent biopsies at 2- and 4-years, provides an opportunity to evaluate the link between metformin use and prostate cancer diagnosis with minimal confounding from screening biases. In diabetic men from REDUCE, we tested the association between metformin use, use of other antidiabetic medications, versus no antidiabetic medication use, and prostate cancer diagnosis as well as prostate cancer grade (low-grade Gleason 4-6 and high-grade Gleason 7-10) using logistic regression. Of the 540 diabetic men with complete data, 205 (38%) did not report use of any antidiabetic medications, 141 (26%) reported use of at least one antidiabetic medication other than metformin, and 194 (36%) reported use of metformin. During the 4-year study, 122 men (23%) were diagnosed with prostate cancer. After adjusting for various clinical and demographic characteristics, we found that metformin use was not significantly associated with total (OR, 1.19; P = 0.50), low-(OR, 1.01; P = 0.96), or high-grade (OR, 1.83; P = 0.19) prostate cancer diagnosis. Likewise, there was no significant association between the use of non-metformin antidiabetic medications and prostate cancer risk in both crude (OR, 1.02; P = 0.95) and multivariable analysis (OR, 0.85; P = 0.56).

Original languageEnglish
Pages (from-to)1055-1060
Number of pages6
JournalCancer Prevention Research
Issue number11
StatePublished - Nov 2015


Dive into the research topics of 'Metformin use and risk of prostate cancer: Results from the REDUCE study'. Together they form a unique fingerprint.

Cite this